Guest Opinions

Tom Walker of Rev1 Ventures addresses the question of whether investors should back biotech start-ups that focus on the coronavirus and other potential pandemics. Here's what you should know.

William Taranto of the Merck Global Health Innovation Fund writes how the switch to working from home can make investors more productive. But the downside is loss of personal interaction.

Times are difficult right now, but promising signs in regard to deals terms, impact investing and engagement are boding well, writes Oliver Libby, managing partner and co-founder of venture firm Hatzimemos / Libby.

The CEO of British Patient Capital writes, borrowing from its own name, that investing patient capital will help lift economy out of the pandemic.

As physical contact is reduced, the need and desire for a touchless economy is stronger than before.

Chief information security officers at firms are discussing the implications for cybersecurity, Robert R Ackerman Jr of AllegisCyber says.

The covid-19 pandemic at the resulting economic downturn is like nothing we have ever experienced. But based on previous recessions, we know new ideas and new solutions are attainable.

Anna Palmer and Chip Hazard discuss with Foundersuite’s Nathan Beckord how and why they back female-led startups and the value the founding team at XFactor brings to its portfolio.

Many venture investors from Asia and elsehwere seem better prepared to emerge from the pandemic and are eager to get their money into circulation.

No one is immune from the pressure to offer a term sheet within 72 hours, and that rapid-fire process may seem nuts to an outsider, writes the managing directors of Sozo Ventures.